The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
Open accessAbstract
P-glycoprotein (Pgp), encoded by the MDR1 gene, is an active efflux pump for many structurally diverse lipophilic compounds. Cellular expression of Pgp results in multidrug resistance (MDR) in vitro and is believed to be a clinically relevant mechanism for tumor resistance to chemotherapy. We have developed a mouse monoclonal antibody, UIC2, that recognizes an extracellular epitope of human Pgp. UIC2 inhibited the efflux of Pgp substrates from MDR cells and significantly increased the cytotoxicity of Pgp-transported drugs, under the conditions where no effect was detectable with other anti-Pgp antibodies. Potentiation of cytotoxicity by UIC2 was observed with all the tested drugs associated with MDR (vinblastine, vincristine, colchicine, taxol, doxorubicin, etoposide, actinomycin D, puromycin, and gramicidin D) but not with any of the drugs to which MDR cells are not cross-resistant (methotrexate, 5-fluorouracil, cis-platinum, G418, and gentamicin). The inhibitory effect of UIC2 in vitro was as strong as that of verapamil (a widely used Pgp inhibitor) at its highest clinically achievable concentrations. Our results suggest that UIC2 or its derivatives provide an alternative or supplement to chemical agents for the reversal of MDR in clinical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearney, J. F., Radbruch, A., Liesegang, B., & Rajewsky, K. (1979) · The Journal of Immunology · doi:10.4049/jimmunol.123.4.1548 · Cited by 1,852
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., & De Clercq, E. (1988) · Journal of Virological Methods · doi:10.1016/0166-0934(88)90134-6 · Cited by 1,642
Expression of Multidrug Resistance Gene in Human Cancers
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., et al. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.2.116 · Cited by 1,290
Pharmacology of drugs that alter multidrug resistance in cancer.
Ford, J. M., & Hait, W. N. (1990) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00045-6 · Cited by 974
Chaudhary, P. M., & Roninson, I. B. (1991) · Cell · doi:10.1016/0092-8674(91)90141-k · Cited by 934
Self-citationDetection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
Kartner, N., Evernden-Porelle, D., Bradley, G., & Ling, V. (1985) · Nature · doi:10.1038/316820a0 · Cited by 908
Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., Von Hoff, D. D., et al. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.18.7160 · Cited by 714
Self-citationHamada, H., & Tsuruo, T. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.20.7785 · Cited by 546
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs
Akiyama, S.-I., Fojo, A., Hanover, J. A., Pastan, I., & Gottesman, M. M. (1985) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01534700 · Cited by 529
Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.
Beck, W. T., Mueller, T. J., & Tanzer, L. R. (1979) · PubMed · Cited by 501
Cited by
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
Litman, T., Druley, T. E., Stein, W. D., & Bates, S. E. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000912 · Cited by 688
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Mechanisms of Drug Resistance in Cancer Chemotherapy
Luqmani, Y. A. (2005) · Medical Principles and Practice · doi:10.1159/000086183 · Cited by 651
Fluorescent cellular indicators are extruded by the multidrug resistance protein.
Homolya, L., Holló, Z., Germann, U. A., Pastan, I., Gottesman, M. M., & Sarkadi, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80566-3 · Cited by 495
Structural insight into substrate and inhibitor discrimination by human P-glycoprotein
Alam, A., Kowal, J., Broude, E., Roninson, I., & Locher, K. P. (2019) · Science · doi:10.1126/science.aav7102 · Cited by 469
Self-citationAn overview of cancer multidrug resistance: a still unsolved problem
Lage, H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8111-5 · Cited by 408
Weisberg, E., & Griffin, J. D. (2000) · Blood · doi:10.1182/blood.v95.11.3498 · Cited by 401
Chaudhary, P., Mechetner, E., & Roninson, I. (1992) · Blood · doi:10.1182/blood.v80.11.2735.2735 · Cited by 379
Self-citationCell biological mechanisms of multidrug resistance in tumors.
Simon, S. M., & Schindler, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3497 · Cited by 369
Molecular mechanisms of drug resistance and its reversal in cancer
Kartal-Yandim, M., Adan-Gokbulut, A., & Baran, Y. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1015957 · Cited by 346
Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 317
Multidrug Resistance Reversal Agents
Robert, J., & Jarry, C. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030183a · Cited by 292
Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Metadata
- Authors
- Mechetner, E. B., & Roninson, I. B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1992-07
- Volume
- 89
- Issue
- 13
- Pages
- 5824-5828
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2078822262
- Cited by
- 316
- References
- 31
- FWCI
- 6.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.